Liang Hongjie, Yan Yulan, Li Taijie, Li Ruolin, Li Meng, Li Shan, Qin Xue
Tumour Biol. 2014 Feb;35(2):1695-701. doi: 10.1007/s13277-013-1234-9.
The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk in the Chinese population has been widely reported, but results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Eligible articles were identified through search of databases including Medline, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM, Chinese), China National Knowledge Infrastructure (CNKI, Chinese), and Wangfang Database (Chinese). The association between the MTHFR polymorphism and breast cancer risk was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Finally, a total of 22 studies with 6,103 cases and 7,913 controls were included in our meta-analysis: 13 studies with 3,273 cases and 4,419 controls for C677T polymorphism and 9 studies with 2,830 cases and 3,494 controls for A1298C polymorphism. With regard to C677T polymorphism, significant association was found with breast cancer risk under three models (T vs. C: OR = 1.12, 95 % CI = 1.02-1.23, P = 0.015; TT vs. CC: OR = 1.35, 95 % CI = 1.10-1.67, P = 0.005; TT vs.
CC/CT: OR = 1.37, 95 % CI = 1.11-1.70, P = 0.004). There was no significant association found between A1298C polymorphism and breast cancer risk under all genetic models (C vs. A: OR = 0.96, 95 % CI = 0.89-1.03, P = 0.268; CC vs. AA: OR = 0.98, 95 % CI = 0.77-1.26, P = 0.899; AC vs. AA: OR = 0.95, 95 % CI = 0.88-1.02, P = 0.174; CC vs. AC/AA: OR = 1.00, 95 % CI = 0.78-1.28, P = 0.996, CC/AC vs. AA: OR = 0.96, 95 % CI = 0.89-1.02, P = 0.196). In summary, during this meta-analysis, we found that MTHFR C677T polymorphism was significantly associated with breast cancer risk in the Chinese population. Meanwhile, MTHFR A1298C polymorphism was not associated with breast cancer risk in the Chinese population.
亚甲基四氢叶酸还原酶（MTHFR）基因多态性与中国人群乳腺癌风险之间的关联已被广泛报道，但结果并不一致。为了更精确地估计两者之间的关系，我们进行了一项荟萃分析。通过检索包括Medline、PubMed、Web of Science、Embase、中国生物医学文献数据库（CBM，中文）、中国知网（CNKI，中文）和万方数据库（中文）在内的数据库来确定符合条件的文章。使用比值比（OR）和95%置信区间（95%CI）来分析MTHFR基因多态性与乳腺癌风险之间的关联。最终，我们的荟萃分析共纳入了22项研究，其中6103例病例和7913例对照：13项研究涉及3273例病例和4419例对照，用于分析C677T多态性；9项研究涉及2830例病例和3494例对照，用于分析A1298C多态性。对于C677T多态性，在三种模型下均发现与乳腺癌风险存在显著关联（T vs. C：OR = 1.12，95%CI = 1.02 - 1.23，P = 0.015；TT vs. CC：OR = 1.35，95%CI = 1.10 - 1.67，P = 0.005；TT vs. CC/CT：OR = 1.37，95%CI = 1.11 - 1.70，P = 0.004）。在所有遗传模型下，均未发现A1298C多态性与乳腺癌风险存在显著关联（C vs. A：OR = 0.96，95%CI = 0.89 - 1.03，P = 0.268；CC vs. AA：OR = 0.98，95%CI = 0.77 - 1.26，P = 0.899；AC vs. AA：OR = 0.95，95%CI = 0.88 - 1.02，P = 0.174；CC vs. AC/AA：OR = 1.00，95%CI = 0.78 - 1.28，P = 0.996，CC/AC vs. AA：OR = 0.96，95%CI = 0.89 - 1.02，P = 0.196）。总之，在本次荟萃分析中，我们发现MTHFR C677T多态性与中国人群乳腺癌风险显著相关。同时，MTHFR A1298C多态性与中国人群乳腺癌风险无关。
